One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...

Obesity is more than just a diet and exercise issue; it's deeply intertwined with psychological and social factors. Experts ...

Experts reveal how to navigate psychological barriers to achieve healthier eating and exercise habits for weight loss.

Scientists found brainstem neurons that tell mice when to stop eating, offering insights for obesity treatments. Columbia ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...

Researchers at Columbia University Irving Medical Center have identified the specific neurons in mice brains that tell them ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

As obesity rates rise across the U.S., a new study from UnitedHealthcare and the Health Action Council examines the financial ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...